



Dermapharm Holding SE: Annual General Meeting approves dividend distribution of EUR 0.88 per share

- » Board of Management and Supervisory Board actions ratified with large majority
- » Shareholders approve EUR 0.88 dividend
- » Distribution ratio: approximately 55% of consolidated net profit
- » 2021 marked by extraordinary growth
- » 2021 outlook confirmed

Grünwald, 23 June 2021 – Dermapharm Holding SE ("Dermapharm"), a rapidly growing manufacturer of branded pharmaceuticals, today successfully held its 2021 Annual General Meeting. 83.94% of the share capital was in attendance at the virtual Annual General Meeting. The majority of shareholders approved the management's proposals under every agenda item.

The Annual General Meeting ratified the actions of the Board of Management and of the Supervisory Board for financial year 2020 with a 97.94% and 87.24% respectively majority of votes cast. At the recommendation of the Board of Management, the Annual General Meeting resolved to distribute a dividend of EUR 0.88 per share. The total distribution will therefore amount to EUR 47.4 million, representing a 55% distribution ratio.

In further votes, the Annual General Meeting approved the Board of Management and Supervisory Board remuneration systems, also with a significant majority of votes cast. Warth & Klein Grant Thornton AG Wirtschaftsprüfungsgesellschaft, Munich, was once again elected to serve as auditors. The detailed results of the voting for each agenda item are available in the Annual General Meeting section of the Company website <https://ir.dermapharm.de>.

In their retrospective on financial year 2020, the Board of Management and the Supervisory Board reiterated not only the special challenges but also the opportunities which arose from the COVID-19 pandemic. With this in mind, they expressed their gratitude to all employees that 2020 could nonetheless end on such a highly successful note. The Board of Management concluded by providing an outlook for the remainder of 2021.

"2020 was characterised by our employees' outstanding commitment to tackling the challenges of the COVID-19 pandemic. The conditions were difficult, yet we managed to achieve our objectives. The high level of expertise on the part of our teams in every segment and our in-house production activities played a vital role in continually maintaining our ability to deliver, as did the establishment of manufacturing facilities for BioNTech's Comirnaty® COVID-19 vaccine at two locations. The successful integration of Allergopharma, the introduction of new, internally developed products and successes in international business have shown that it is possible to implement our growth strategy even under difficult conditions", said Dr Hans-Georg Feldmeier, Chairman of the Board of Management of Dermapharm Holding SE.

Based on the good start to the 2021 financial year, the Board of Management has confirmed its outlook for the rest of the year. Thanks not only to the expansion of vaccine production but also to organic growth, Dermapharm believes that it is well equipped to achieve the ambitious targets set for the current financial year.



Company profile:

Dermapharm – Pharmaceutical Excellence "Made in Germany"

Dermapharm is a rapidly growing manufacturer of branded pharmaceuticals. Founded in 1991, the Company is based in Grünwald near Munich. The Company's integrated business model comprises in-house development, production and the distribution of brand products by a trained pharmaceutical sales force. In addition to its main location in Brehna near Leipzig, Dermapharm also operates other production, development and distribution locations in Europe (primarily in Germany) and the United States.

In the "Branded pharmaceuticals and other healthcare products" segment, Dermapharm has more than 1,300 marketing authorisations with more than 380 active pharmaceutical ingredients. Dermapharm's portfolio of pharmaceuticals, medical devices and food supplements are tailored to selected therapeutic areas in which the Company is a market leader, especially in Germany.

In the "Herbal extracts" segment, Dermapharm can tap the expertise of the Spanish company Euromed S.A., a leading global manufacturer of herbal extracts and plant-based active ingredients for the pharmaceuticals, nutraceuticals, foodstuffs and cosmetics industries.

Dermapharm's business model also includes the "Parallel import business" segment that operates under the "axicorp" brand. Based on revenue, Dermapharm was among the top five parallel import companies in Germany in 2020.

With a consistent R&D strategy and numerous successful product and company acquisitions and by stepping up its internationalisation efforts, Dermapharm has continuously optimised its business over the past 30 years and sought external growth opportunities in addition to organic growth. Dermapharm is firmly committed to continuing on this profitable growth course in the future.

Contact

Investor Relations & Corporate Communications

Britta Hamberger

Tel.: +49 (0)89 – 64186-233

Fax: +49 (0)89 – 64186-165

E-mail: ir@dermapharm.com